1,721,325 research outputs found
Cardio-metabolic comorbidities in patients with psoriasis
No full textFil: Cozzi, Alessandra. University of Verona. Department of Medicine. Section of Dermatology and Venereology; ItalyFil: Gisondi, Paolo. University of Verona. Department of Medicine. Section of Dermatology and Venereology; ItalyFil: Girolomoni, Giampiero. University of Verona. Department of Medicine. Section of Dermatology and Venereology; Ital
Hyperuricemia in patients with chronic plaque psoriasis
No full textPsoriasis is frequently associated with obesity, which may favor the development of hyperuricemia. Hyperuricemia predisposes patients to gout arthritis and is an emerging cardiovascular risk factor. In this study, we investigated the prevalence of hyperuricemia and serum uric acid (SUA) levels in psoriatic patients. SUA was measured in consecutive psoriatic patients (n = 338) and prevalence of hyperuricemia was estimated. Hyperuricemia was defined as SUA ≥7 mg/dL in men and ≥6 mg/dL in women. Hyperuricemia affected 20% (67 out 338) of patients with psoriasis. SUA levels were 5.8 ± 1.6 (mean ± SD) in patients with psoriasis. Levels of SUA were significantly higher in obese patients compared to non-obese patients (6.1 ± 1.5 vs 5.2 ± 1.4, P < 0.05). Levels of SUA showed a significant, positive correlation with body mass index (r = 0.30; P < 0.01) and serum triglycerides (r = 0.31; P < 0.01) but they were not significantly associated with age, sex, psoriasis duration or Psoriasis Area Severity Index score. Hyperuricemia is a common finding in psoriatic patients. Dosing levels of SUA could be appropriate in the global management of patients with psoriasis, particularly in those who are obese and with serum triglycerides upper the normal range
Psoriasis and systemic inflammation: underdiagnosed enthesopathy
No full textOur understanding of the pathogenesis of psoriasis is changing rapidly and the traditional view that it is a disease limited to the skin continues to be challenged. Indeed, there is convincing evidence that psoriasis patients have a higher prevalence of comorbid disease, particularly cardio-metabolic disorders and psoriatic arthritis (PsA). The results of recent investigations into psoriasis and cardiovascular or metabolic comorbidities provide increasing evidence for a possible shared pathogenic mechanism for these disorders, linked by an underlying chronic systemic inflammatory state. This highlights the importance of investigating associated comorbidities beyond skin manifestations. Psoriatic arthritis is a chronic inflammatory arthropathy that can occur in association with psoriasis and most commonly affects the distal joints in the hands and feet. Skin lesions precede arthritic symptoms in approximately 75% of cases; typically, the cutaneous manifestations of the disease develop 10 years prior to the onset of joint symptoms. This disease course, therefore, provides a potential window of opportunity to initiate effective and aggressive therapies to prevent long-term damage, if symptoms of PsA can be detected early. One of the major features of PsA is enthesitis, yet clinically asymptomatic cases of entheseal abnormalities are likely to go undiagnosed. This concept was evaluated in a prospective study in which entheseal changes in clinically asymptomatic psoriasis patients were compared with findings from a control group. Ultrasonography detected a significantly higher incidence of entheseal abnormalities in patients with psoriasis, despite the absence of clinical symptoms of arthropathy. Ongoing monitoring of these patients has also revealed that a higher baseline score for enthesitis may be associated with a more severe psoriasis outcome. These findings demonstrate that detecting early signs of PsA in asymptomatic patients with psoriasis may have the potential to positively influence disease prognosis and ultimately clinical outcome. Dermatologists can, therefore, play a key role in the early detection and management of PsA
Glomerular filtration rate in patients with psoriasis treated with etanercept
No full textObjective: To estimate the prevalence of chronic kidney disease (CKD) and evaluate renal function in patients with moderate-to-severe chronic plaque psoriasis treated with etanercept (an anti-tumour necrosis factor-a drug). Methods: This retrospective cohort study included patients with moderate-to-severe chronic plaque psoriasis. Kidney function was evaluated using estimated glomerular filtration rate (EGFR). Results: The prevalence of CKD at baseline was 3.9% (two of 51 patients). EGFR was unaffected by etanercept therapy (83.623.9 at baseline vs 82.221.6 ml/min per 1.73m2 after 6 months). Conclusion: EGFR was unaffected by 6 months’ etanercept treatment. Physicians should be aware of the risk of CKD when providing comprehensive care to patients with moderate-to-severe psoriasi
Scurvy as Presenting Sign of Anorexia Nervosa
Full text linkA 59-year-old woman with history of anorexia nervosa presented with striped purpura and ecchymoses on the legs. Deficiency in serum vitamin C with levels <0.1 mg/dl (N.V. 0.2-2mg/dL) was found
The "difficult patient with psoriasis", i.e. patient with moderate to severe psoriasis and metabolic comorbidities
No full textThe "difficult patient with psoriasis", i.e. patient with moderate to severe psoriasis and metabolic comorbiditie
The efficacy and safety of topical pimecrolimus in pediatric patients with atopic dermatitis.
No full textPimecrolimus is a calcineurin inhibitor developed for the topical treatment of atopic dermatitis. It selectively targets T cells and mast cells, but since it has no effects on dendritic cells, endothelial cells and fibroblasts, it does not induce skin atrophy. Pimercolimus was effective, well-tolerated and safe in infants, children and adolescents with mild to moderate atopic dermatitis in several randomized control trials. Given the low capacity of the drug to permeate through the skin, there is no evidence of systemic immunosuppression from topical pimecrolimus therapy
Impact of TNF-α antagonists on the quality of life in selected skin diseases
No full textVengono riassunte le implicazioni sulla qualità della vita di malattie infiammatorie dermatologiche, e l'efficacia della terapia con farmaci anti-TNF alpha su parametri correlati con la qualità di vit
Psoriasis and athero-thrombotic diseases: disease specific and non disease specific risk factors.
No full textPsoriasis is associated with systemic inflammation and cardiovascular risk facto
- …
